Integrated Financials for the Financial Year Ended 31st March 2025

Ebitda Margin ExpansionResults View source PDF Explain this filing

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹715.00

prior close

₹721.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-3.0% vs market

Pharmaceuticals peers, median of 150sector+0.2%-2.4% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-2.3

15m

-1.9

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+0.8-3.0+0.2-2.4

Next day

-1.2+2.0-3.2+1.1-2.4

-3.1+0.9-4.0+0.2-3.3

+0.3+1.7-1.4+1.0-0.7

+2.2+1.6+0.7+1.2+1.1

+0.0+2.2-2.2+0.7-0.7

+2.0+2.7-0.8+1.2+0.8

15d

-0.1+4.5-4.6+0.8-0.9

-2.5+5.6-8.1+2.2-4.7

-1.0+9.0-10.0+4.1-5.1

-0.6+3.5-4.1-0.9+0.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amrutanjan Health Care reported FY25 revenue from operations of ₹451.82 crore, up about 7.3% from ₹421.23 crore in FY24. Profit after tax grew roughly 13% to ₹50.83 crore from ₹44.97 crore, translating to EPS of ₹17.58 versus ₹15.50. Q4 FY25 revenue was ₹135.41 crore (up ~6.6% YoY) with Q4 PAT at ₹15.18 crore (up ~11% YoY). Operating cash flow improved sharply to ₹50.90 crore from ₹27.91 crore, and cash on hand nearly tripled to ₹10.16 crore. The board has recommended a final dividend of ₹2.60 per share, on top of an interim ₹1.00 already paid during the year. The auditor (B S R & Co. LLP) issued an unmodified opinion, and the current Company Secretary retires on 31 May 2025 with a successor appointed from 1 June 2025.

Likely market impact

Steady mid-single-digit revenue growth and double-digit profit growth, supported by strong operating cash generation, is a constructive signal for shareholders. The total dividend of ₹3.60 per share offers a reasonable yield, while higher capex (₹35.55 crore vs ₹6.72 crore) and expansion of capital work-in-progress suggest the company is investing in future capacity, which could weigh on near-term margins if revenue growth does not accelerate.